cached image

Darryle Schoepp - Publications

Affiliations: 
Merck Research Laboratories, Boston, MA, United States 
Area:
Glutamate

203 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Feldman HH, Haas M, Gandy S, Schoepp DD, Cross AJ, Mayeux R, Sperling RA, Fillit H, van de Hoef DL, Dougal S, Nye JS. Alzheimer's disease research and development: a call for a new research roadmap. Annals of the New York Academy of Sciences. 1313: 1-16. PMID 24754377 DOI: 10.1111/nyas.12424  1
2013 Wright RA, Johnson BG, Zhang C, Salhoff C, Kingston AE, Calligaro DO, Monn JA, Schoepp DD, Marek GJ. CNS distribution of metabotropic glutamate 2 and 3 receptors: transgenic mice and [³H]LY459477 autoradiography. Neuropharmacology. 66: 89-98. PMID 22313530 DOI: 10.1016/j.neuropharm.2012.01.019  1
2011 Schoepp DD. Where will new neuroscience therapies come from? Nature Reviews. Drug Discovery. 10: 715-6. PMID 21959271 DOI: 10.1038/nrd3559  1
2011 Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, Potter WZ, Lee CM. Translating glutamate: from pathophysiology to treatment. Science Translational Medicine. 3: 102mr2. PMID 21957170 DOI: 10.1126/scitranslmed.3002804  1
2011 Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD, Wroblewski JT, Pin JP. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. 60: 1017-41. PMID 21036182 DOI: 10.1016/j.neuropharm.2010.10.022  1
2009 Linden AM, Johnson BG, Trokovic N, Korpi ER, Schoepp DD. Use of MGLUR2 and MGLUR3 knockout mice to explore in vivo receptor specificity of the MGLUR2/3 selective antagonist LY341495. Neuropharmacology. 57: 172-82. PMID 19477188 DOI: 10.1016/j.neuropharm.2009.05.002  1
2008 Nicoletti F, Collingridge G, Schoepp D. 2008 Eruptions in metabotropic glutamate receptors Neuropharmacology. 55: 391. PMID 18638495 DOI: 10.1016/j.neuropharm.2008.07.003  1
2008 Fell MJ, Svensson KA, Johnson BG, Schoepp DD. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). The Journal of Pharmacology and Experimental Therapeutics. 326: 209-17. PMID 18424625 DOI: 10.1124/jpet.108.136861  1
2008 Conn PJ, Tamminga C, Schoepp DD, Lindsley C. Schizophrenia: moving beyond monoamine antagonists. Molecular Interventions. 8: 99-107. PMID 18403654 DOI: 10.1124/mi.8.2.7  1
2008 Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 1603-10. PMID 17712352 DOI: 10.1038/sj.npp.1301531  1
2008 Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder (Neuropsychopharmacology (2007) DOI: 10.1038/sj.npp.1301531) Neuropsychopharmacology. 33: 2549. DOI: 10.1038/sj.npp.1301622  1
2007 Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, ... ... Schoepp DD, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine. 13: 1102-7. PMID 17767166 DOI: 10.1038/nm1632  1
2007 Witkin JM, Marek GJ, Johnson BG, Schoepp DD. Metabotropic glutamate receptors in the control of mood disorders. Cns & Neurological Disorders Drug Targets. 6: 87-100. PMID 17430147 DOI: 10.2174/187152707780363302  1
2007 Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology. 193: 121-36. PMID 17384937 DOI: 10.1007/s00213-007-0758-3  1
2007 Monn JA, Massey SM, Valli MJ, Henry SS, Stephenson GA, Bures M, Hérin M, Catlow J, Giera D, Wright RA, Johnson BG, Andis SL, Kingston A, Schoepp DD. Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. Journal of Medicinal Chemistry. 50: 233-40. PMID 17228865 DOI: 10.1021/jm060917u  1
2007 Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039). The Journal of Pharmacology and Experimental Therapeutics. 321: 308-17. PMID 17204749 DOI: 10.1124/jpet.106.110809  1
2006 Marek GJ, Wright RA, Schoepp DD. 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740. Neuroscience Letters. 403: 256-60. PMID 16759803 DOI: 10.1016/j.neulet.2006.05.021  1
2006 Linden AM, Baez M, Bergeron M, Schoepp DD. Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus. Neuropharmacology. 51: 213-28. PMID 16733060 DOI: 10.1016/j.neuropharm.2006.03.014  1
2006 Weiss B, Alt A, Ogden AM, Gates M, Dieckman DK, Clemens-Smith A, Ho KH, Jarvie K, Rizkalla G, Wright RA, Calligaro DO, Schoepp D, Mattiuz EL, Stratford RE, Johnson B, et al. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. The Journal of Pharmacology and Experimental Therapeutics. 318: 772-81. PMID 16690725 DOI: 10.1124/jpet.106.101428  1
2006 Rodd ZA, McKinzie DL, Bell RL, McQueen VK, Murphy JM, Schoepp DD, McBride WJ. The metabotropic glutamate 2/3 receptor agonist LY404039 reduces alcohol-seeking but not alcohol self-administration in alcohol-preferring (P) rats. Behavioural Brain Research. 171: 207-15. PMID 16678921 DOI: 10.1016/j.bbr.2006.03.032  1
2006 Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD, McKinzie DL. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. The Journal of Pharmacology and Experimental Therapeutics. 316: 905-13. PMID 16223873 DOI: 10.1124/jpet.105.091926  1
2006 Linden AM, Schoepp DD. Metabotropic glutamate receptor targets for neuropsychiatric disorders Drug Discovery Today: Therapeutic Strategies. 3: 507-517. DOI: 10.1016/j.ddstr.2006.10.018  1
2006 Mathews WB, Monn JA, Ravert HT, Holt DP, Schoepp DD, Dannals RF. Synthesis of a mGluR5 antagonist using [11C]cOpper(I) cyanide Journal of Labelled Compounds and Radiopharmaceuticals. 49: 829-834. DOI: 10.1002/jlcr.1100  1
2005 Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 48: 913-22. PMID 16364896 DOI: 10.1016/j.neuron.2005.10.028  1
2005 González R, Collado I, de Uralde BL, Marcos A, Martín-Cabrejas LM, Pedregal C, Blanco-Urgoiti J, Pérez-Castells J, Fernández MA, Andis SL, Johnson BG, Wright RA, Schoepp DD, Monn JA. C3'-cis-Substituted carboxycyclopropyl glycines as metabotropic glutamate 2/3 receptor agonists: synthesis and SAR studies. Bioorganic & Medicinal Chemistry. 13: 6556-70. PMID 16153851 DOI: 10.1016/j.bmc.2005.07.036  1
2005 Bueno AB, Collado I, de Dios A, Domínguez C, Martín JA, Martín LM, Martínez-Grau MA, Montero C, Pedregal C, Catlow J, Coffey DS, Clay MP, Dantzig AH, Lindstrom T, Monn JA, ... ... Schoepp DD, et al. Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. Journal of Medicinal Chemistry. 48: 5305-20. PMID 16078848 DOI: 10.1021/jm050235r  1
2005 Nie Y, Schoepp DD, Klaunig JE, Yard M, Lahiri DK, Kubek MJ. Thyrotropin-releasing hormone (protirelin) inhibits potassium-stimulated glutamate and aspartate release from hippocampal slices in vitro. Brain Research. 1054: 45-54. PMID 16055093 DOI: 10.1016/j.brainres.2005.06.077  1
2005 Linden AM, Bergeron M, Schoepp DD. Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo. Neuropharmacology. 49: 120-34. PMID 16023151 DOI: 10.1016/j.neuropharm.2005.05.006  1
2005 Dominguez C, Prieto L, Valli MJ, Massey SM, Bures M, Wright RA, Johnson BG, Andis SL, Kingston A, Schoepp DD, Monn JA. Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist. Journal of Medicinal Chemistry. 48: 3605-12. PMID 15887967 DOI: 10.1021/jm040222y  1
2005 Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, Schoepp DD. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology. 179: 271-83. PMID 15717213 DOI: 10.1007/s00213-004-2099-9  1
2005 Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Reviews. Drug Discovery. 4: 131-44. PMID 15665858 DOI: 10.1038/nrd1630  1
2005 Linden AM, Shannon H, Baez M, Yu JL, Koester A, Schoepp DD. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice. Psychopharmacology. 179: 284-91. PMID 15619115 DOI: 10.1007/s00213-004-2098-x  1
2005 Wheeler WJ, Clodfelter DK, Collado I, Kulanthaivel P, Pedregal C, Stoddard EA, Wright RA, Schoepp DD. (2S,1'S,2'R,3'R)-2(2'-Carboxy-3'-hydroxymethylcyclopropyl)glycine-[3H], a potent and selective radioligand for labeling group 2 and 3 metabotropic glutamate receptors. Bioorganic & Medicinal Chemistry Letters. 15: 349-51. PMID 15603952 DOI: 10.1016/j.bmcl.2004.10.093  1
2005 Feinberg I, Schoepp DD, Hsieh KC, Darchia N, Campbell IG. The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats. The Journal of Pharmacology and Experimental Therapeutics. 312: 826-33. PMID 15383637 DOI: 10.1124/jpet.104.076547  1
2004 Carter K, Dickerson J, Schoepp DD, Reilly M, Herring N, Williams J, Sallee FR, Sharp JW, Sharp FR. The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis. Neuropharmacology. 47: 1135-45. PMID 15567423 DOI: 10.1016/j.neuropharm.2004.08.018  1
2004 Barda DA, Wang ZQ, Britton TC, Henry SS, Jagdmann GE, Coleman DS, Johnson MP, Andis SL, Schoepp DD. SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide. Bioorganic & Medicinal Chemistry Letters. 14: 3099-102. PMID 15149652 DOI: 10.1016/j.bmcl.2004.04.017  1
2004 Collado I, Pedregal C, Bueno AB, Marcos A, González R, Blanco-Urgoiti J, Pérez-Castells J, Schoepp DD, Wright RA, Johnson BG, Kingston AE, Moher ED, Hoard DW, Griffey KI, Tizzano JP. (2S,1'S,2'R,3'R)-2-(2'-Carboxy-3'-hydroxymethylcyclopropyl) glycine is a highly potent group 2 and 3 metabotropic glutamate receptor agonist with oral activity. Journal of Medicinal Chemistry. 47: 456-66. PMID 14711315 DOI: 10.1021/jm030967o  1
2004 Linden AM, Greene SJ, Bergeron M, Schoepp DD. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 29: 502-13. PMID 14694349 DOI: 10.1038/sj.npp.1300321  1
2004 Swanson CJ, Perry KW, Schoepp DD. The mGlu2/3 receptor agonist, LY354740, blocks immobilization-induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex. Journal of Neurochemistry. 88: 194-202. PMID 14675163  1
2003 Swanson CJ, Schoepp DD. A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists. Annals of the New York Academy of Sciences. 1003: 309-17. PMID 14684454 DOI: 10.1196/annals.1300.019  1
2003 Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress (Amsterdam, Netherlands). 6: 189-97. PMID 13129812 DOI: 10.1080/1025389031000146773  1
2003 Linden AM, Baez M, Bergeron M, Schoepp DD. Increased c-Fos expression in the centromedial nucleus of the thalamus in metabotropic glutamate 8 receptor knockout mice following the elevated plus maze test. Neuroscience. 121: 167-78. PMID 12946709 DOI: 10.1016/S0306-4522(03)00393-2  1
2003 Linden AM, Bergeron M, Baez M, Schoepp DD. Systemic administration of the potent mGlu8 receptor agonist (S)-3,4-DCPG induces c-Fos in stress-related brain regions in wild-type, but not mGlu8 receptor knockout mice. Neuropharmacology. 45: 473-83. PMID 12907308 DOI: 10.1016/S0028-3908(03)00200-4  1
2003 Johnson MP, Baez M, Jagdmann GE, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. Journal of Medicinal Chemistry. 46: 3189-92. PMID 12852748 DOI: 10.1021/jm034015u  1
2003 Waterhouse RN, Schmidt ME, Sultana A, Schoepp DD, Wheeler WJ, Mozley PD, Laruelle M. Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivo. Nuclear Medicine and Biology. 30: 187-90. PMID 12623118 DOI: 10.1016/S0969-8051(02)00423-7  1
2003 Sørensen US, Bleisch TJ, Kingston AE, Wright RA, Johnson BG, Schoepp DD, Ornstein PL. Synthesis and structure-activity relationship studies of novel 2-diarylethyl substituted (2-carboxycycloprop-1-yl)glycines as high-affinity group II metabotropic glutamate receptor ligands. Bioorganic & Medicinal Chemistry. 11: 197-205. PMID 12470714 DOI: 10.1016/S0968-0896(02)00387-5  1
2002 Swanson CJ, Schoepp DD. The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats. The Journal of Pharmacology and Experimental Therapeutics. 303: 919-27. PMID 12438510 DOI: 10.1124/jpet.102.038422  1
2002 Schoepp DD, Conn PJ. Metabotropic glutamate receptors. Pharmacology, Biochemistry, and Behavior. 74: 255-6. PMID 12376174 DOI: 10.1016/S0091-3057(02)00953-X  1
2002 Kingston AE, Griffey K, Johnson MP, Chamberlain MJ, Kelly G, Tomlinson R, Wright RA, Johnson BG, Schoepp DD, Harris JR, Clark BP, Baker RS, Tizzano JT. Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagonists. Neuroscience Letters. 330: 127-30. PMID 12231428 DOI: 10.1016/S0304-3940(02)00751-6  1
2002 Linden AM, Johnson BG, Peters SC, Shannon HE, Tian M, Wang Y, Yu JL, Köster A, Baez M, Schoepp DD. Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor. Neuropharmacology. 43: 251-9. PMID 12213279 DOI: 10.1016/S0028-3908(02)00079-5  1
2002 Collado I, Pedregal C, Mazón A, Espinosa JF, Blanco-Urgoiti J, Schoepp DD, Wright RA, Johnson BG, Kingston AE. (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-methylcyclopropyl) glycine is a potent and selective metabotropic group 2 receptor agonist with anxiolytic properties. Journal of Medicinal Chemistry. 45: 3619-29. PMID 12166935 DOI: 10.1021/jm0110486  1
2002 Feinberg I, Campbell IG, Schoepp DD, Anderson K. The selective group mGlu2/3 receptor agonist LY379268 suppresses REM sleep and fast EEG in the rat. Pharmacology, Biochemistry, and Behavior. 73: 467-74. PMID 12117602 DOI: 10.1016/S0091-3057(02)00843-2  1
2002 Tizzano JP, Griffey KI, Schoepp DD. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacology, Biochemistry, and Behavior. 73: 367-74. PMID 12117591 DOI: 10.1016/S0091-3057(02)00850-X  1
2002 Clark M, Johnson BG, Wright RA, Monn JA, Schoepp DD. Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats. Pharmacology, Biochemistry, and Behavior. 73: 339-46. PMID 12117588 DOI: 10.1016/S0091-3057(02)00848-1  1
2002 Schoepp DD. Metabotropic glutamate receptors. Pharmacology, Biochemistry, and Behavior. 73: 285-6. PMID 12117581 DOI: 10.1016/S0091-3057(02)00824-9  1
2001 Coplan JD, Mathew SJ, Smith EL, Trost RC, Scharf BA, Martinez J, Gorman JM, Monn JA, Schoepp DD, Rosenblum LA. Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamic-pituitary-adrenal axis and noradrenergic function. Cns Spectrums. 6: 607-12, 617. PMID 15573025  1
2001 Mathew SJ, Coplan JD, Schoepp DD, Smith EL, Rosenblum LA, Gorman JM. Glutamate-hypothalamic-pituitary-adrenal axis interactions: implications for mood and anxiety disorders. Cns Spectrums. 6: 555-6, 561-4. PMID 15573019  1
2001 Marek GJ, Wright RA, Gewirtz JC, Schoepp DD. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience. 105: 379-92. PMID 11672605 DOI: 10.1016/S0306-4522(01)00199-3  1
2001 Schoepp DD. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. The Journal of Pharmacology and Experimental Therapeutics. 299: 12-20. PMID 11561058  1
2001 Wright RA, Arnold MB, Wheeler WJ, Ornstein PL, Schoepp DD. [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. The Journal of Pharmacology and Experimental Therapeutics. 298: 453-60. PMID 11454905  1
2001 Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD. Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology. 40: 847-55. PMID 11378155 DOI: 10.1016/S0028-3908(01)00034-X  1
2001 Thomas NK, Wright RA, Howson PA, Kingston AE, Schoepp DD, Jane DE. (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology. 40: 311-8. PMID 11166323 DOI: 10.1016/S0028-3908(00)00169-6  1
2000 Wright RA, Arnold MB, Wheeler WJ, Ornstein PL, Schoepp DD. Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn-Schmiedeberg's Archives of Pharmacology. 362: 546-54. PMID 11138847 DOI: 10.1007/s002100000305  1
2000 Cartmell J, Salhoff CR, Perry KW, Monn JA, Schoepp DD. Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum. Brain Research. 887: 378-84. PMID 11134627 DOI: 10.1016/S0006-8993(00)03067-5  1
2000 Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, Schoepp DD, Lodge D, Collingridge GL. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. British Journal of Pharmacology. 131: 239-44. PMID 10991916 DOI: 10.1038/sj.bjp.0703574  1
2000 Cartmell J, Monn JA, Schoepp DD. The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. European Journal of Pharmacology. 400: 221-4. PMID 10988337 DOI: 10.1016/S0014-2999(00)00423-4  1
2000 Bond A, Jones NM, Hicks CA, Whiffin GM, Ward MA, O'Neill MF, Kingston AE, Monn JA, Ornstein PL, Schoepp DD, Lodge D, O'Neill MJ. Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo. The Journal of Pharmacology and Experimental Therapeutics. 294: 800-9. PMID 10945827  1
2000 Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD. The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat. Journal of Neurochemistry. 75: 1147-54. PMID 10936197 DOI: 10.1046/j.1471-4159.2000.0751147.x  1
2000 Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. Journal of Neurochemistry. 75: 889-907. PMID 10936169 DOI: 10.1046/j.1471-4159.2000.0750889.x  1
2000 Cartmell J, Monn JA, Schoepp DD. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology. 148: 423-9. PMID 10928316  1
2000 Chen Y, Bacon G, Sher E, Clark BP, Kallman MJ, Wright RA, Johnson BG, Schoepp DD, Kingston AE. Evaluation of the activity of a novel metabotropic glutamate receptor antagonist (+/-)-2-amino-2-(3-cis and trans-carboxycyclobutyl-3-(9-thioxanthyl)propionic acid) in the in vitro neonatal spinal cord and in an in vivo pain model. Neuroscience. 95: 787-93. PMID 10670446 DOI: 10.1016/S0306-4522(99)00496-0  1
2000 Cartmell J, Monn JA, Schoepp DD. Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268. Naunyn-Schmiedeberg's Archives of Pharmacology. 361: 39-46. PMID 10651145 DOI: 10.1007/s002109900151  1
2000 Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. The Journal of Pharmacology and Experimental Therapeutics. 292: 76-87. PMID 10604933  1
2000 Monn JA, Schoepp DD. Chapter 1. Metabotropic glutamate receptor modulators: Recent advances and therapeutic potential Annual Reports in Medicinal Chemistry. 35: 1-10.  1
1999 Kingston AE, O'Neill MJ, Bond A, Bruno V, Battaglia G, Nicoletti F, Harris JR, Clark BP, Monn JA, Lodge D, Schoepp DD. Neuroprotective actions of novel and potent ligands of group I and group II metabotropic glutamate receptors. Annals of the New York Academy of Sciences. 890: 438-49. PMID 10668448  1
1999 Lam AG, Monn JA, Schoepp DD, Lodge D, McCulloch J. Group II selective metabotropic glutamate receptor agonists and local cerebral glucose use in the rat. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 19: 1083-91. PMID 10532632 DOI: 10.1097/00004647-199910000-00004  1
1999 Johnson BG, Wright RA, Arnold MB, Wheeler WJ, Ornstein PL, Schoepp DD. [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 38: 1519-29. PMID 10530814 DOI: 10.1016/S0028-3908(99)00053-2  1
1999 Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology. 38: 1431-76. PMID 10530808 DOI: 10.1016/S0028-3908(99)00092-1  1
1999 Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. The Journal of Pharmacology and Experimental Therapeutics. 291: 161-70. PMID 10490900  1
1999 Kingston AE, O'Neill MJ, Lam A, Bales KR, Monn JA, Schoepp DD. Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795. European Journal of Pharmacology. 377: 155-65. PMID 10456425 DOI: 10.1016/S0014-2999(99)00397-0  1
1999 Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR, Grutsch JL, Wright RA, Johnson BG, Andis SL, Kingston A, Tomlinson R, Lewis R, Griffey KR, ... ... Schoepp DD, et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. Journal of Medicinal Chemistry. 42: 1027-40. PMID 10090786 DOI: 10.1021/jm980616n  1
1999 Schoepp DD, Monn JA, Marek GJ, Aghajanian G, Moghaddam B. LY354740: A systemically active mGlu2/mGlu3 receptor agonist Cns Drug Reviews. 5: 1-12.  1
1998 Fitzjohn SM, Bortolotto ZA, Palmer MJ, Doherty AJ, Ornstein PL, Schoepp DD, Kingston AE, Lodge D, Collingridge GL. The potent mGlu receptor antagonist LY341495 identifies roles for both cloned and novel mGlu receptors in hippocampal synaptic plasticity. Neuropharmacology. 37: 1445-58. PMID 9886667 DOI: 10.1016/S0028-3908(98)00145-2  1
1998 Collado I, Ezquerra J, Mazón A, Pedregal C, Yruretagoyena B, Kingston AE, Tomlinson R, Wright RA, Johnson BG, Schoepp DD. 2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors. Bioorganic & Medicinal Chemistry Letters. 8: 2849-54. PMID 9873635 DOI: 10.1016/S0960-894X(98)00510-1  1
1998 Valli MJ, Schoepp DD, Wright RA, Johnson BG, Kingston AE, Tomlinson R, Monn JA. Synthesis and metabotropic glutamate receptor antagonist activity of N1-substituted analogs of 2R,4R-4-aminopyrrolidine-2,4-dicarboxylic acid. Bioorganic & Medicinal Chemistry Letters. 8: 1985-90. PMID 9873471 DOI: 10.1016/S0960-894X(98)00352-7  1
1998 Ornstein PL, Arnold MB, Bleisch TJ, Wright RA, Wheeler WJ, Schoepp DD. [3H]LY341495, a highly potent, selective and novel radioligand for labeling Group II metabotropic glutamate receptors. Bioorganic & Medicinal Chemistry Letters. 8: 1919-22. PMID 9873459 DOI: 10.1016/S0960-894X(98)00329-1  1
1998 Ornstein PL, Arnold MB, Lunn WH, Heinz LJ, Leander JD, Lodge D, Schoepp DD. Heteroatom-substitution as a strategy for increasing the potency of competitive NMDA antagonists. Bioorganic & Medicinal Chemistry Letters. 8: 389-94. PMID 9871691 DOI: 10.1016/S0960-894X(98)00038-9  1
1998 Sang CN, Hostetter MP, Gracely RH, Chappell AS, Schoepp DD, Lee G, Whitcup S, Caruso R, Max MB. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology. 89: 1060-7. PMID 9821993  1
1998 Lam AG, Soriano MA, Monn JA, Schoepp DD, Lodge D, McCulloch J. Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia. Neuroscience Letters. 254: 121-3. PMID 9779935 DOI: 10.1016/S0304-3940(98)00651-X  1
1998 Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Monn JA. Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist. Naunyn-Schmiedeberg's Archives of Pharmacology. 358: 175-80. PMID 9750002  1
1998 Kingston AE, Ornstein PL, Wright RA, Johnson BG, Mayne NG, Burnett JP, Belagaje R, Wu S, Schoepp DD. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology. 37: 1-12. PMID 9680254 DOI: 10.1016/S0028-3908(97)00191-3  1
1998 Wu S, Wright RA, Rockey PK, Burgett SG, Arnold JS, Rosteck PR, Johnson BG, Schoepp DD, Belagaje RM. Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Research. Molecular Brain Research. 53: 88-97. PMID 9473604 DOI: 10.1016/S0169-328X(97)00277-5  1
1998 Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, Tizzano JP, Helton DR, Kallman MJ, Schoepp DD, Hérin M. 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability. Journal of Medicinal Chemistry. 41: 358-78. PMID 9464367 DOI: 10.1021/jm970498o  1
1998 Ornstein PL, Bleisch TJ, Arnold MB, Wright RA, Johnson BG, Schoepp DD. 2-Substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 1. Effects of alkyl, arylalkyl, and diarylalkyl substitution. Journal of Medicinal Chemistry. 41: 346-57. PMID 9464366 DOI: 10.1021/jm970497w  1
1998 Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. The Journal of Pharmacology and Experimental Therapeutics. 284: 651-60. PMID 9454811  1
1998 Escribano A, Ezquerra J, Pedregal C, Rubio A, Yruretagoyena B, Baker SR, Wright RA, Johnson BG, Schoepp DD. (2S,3S)-2-Amino-3-(2,2-diphenylethyl)pentanedioic acid selective group 2 metabotropic glutamate receptor antagonist Bioorganic and Medicinal Chemistry Letters. 8: 765-770. DOI: 10.1016/S0960-894X(98)00091-2  1
1997 Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ. LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology. 36: 1511-6. PMID 9517421 DOI: 10.1016/S0028-3908(97)00170-6  1
1997 Clarke VR, Ballyk BA, Hoo KH, Mandelzys A, Pellizzari A, Bath CP, Thomas J, Sharpe EF, Davies CH, Ornstein PL, Schoepp DD, Kamboj RK, Collingridge GL, Lodge D, Bleakman D. A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission. Nature. 389: 599-603. PMID 9335499 DOI: 10.1038/39315  1
1997 Battaglia G, Monn JA, Schoepp DD. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neuroscience Letters. 229: 161-4. PMID 9237483 DOI: 10.1016/S0304-3940(97)00442-4  1
1997 Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Mayne NG, Wu S, Cockerman SL, Burnett JP, Belegaje R, Bleakman D, Monn JA. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology. 36: 1-11. PMID 9144636 DOI: 10.1016/S0028-3908(96)00160-8  1
1997 Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR, Schoepp DD. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. Journal of Medicinal Chemistry. 40: 528-37. PMID 9046344 DOI: 10.1021/jm9606756  1
1997 Bleisch TJ, Ornstein PL, Allen NK, Wright RA, Lodge D, Schoepp DD. Structure-activity studies of aryl-spaced decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists Bioorganic and Medicinal Chemistry Letters. 7: 1161-1166. DOI: 10.1016/S0960-894X(97)00185-6  1
1996 Bleakman D, Ballyk BA, Schoepp DD, Palmer AJ, Bath CP, Sharpe EF, Woolley ML, Bufton HR, Kamboj RK, Tarnawa I, Lodge D. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology. 35: 1689-702. PMID 9076748 DOI: 10.1016/S0028-3908(96)00156-6  1
1996 Schoepp DD, Salhoff CR, Wright RA, Johnson BG, Burnett JP, Mayne NG, Belagaje R, Wu S, Monn JA. The novel metabotropic glutamate receptor agonist 2R,4R-APDC potentiates stimulation of phosphoinositide hydrolysis in the rat hippocampus by 3,5-dihydroxyphenylglycine: evidence for a synergistic interaction between group 1 and group 2 receptors. Neuropharmacology. 35: 1661-72. PMID 9076745 DOI: 10.1016/S0028-3908(96)00121-9  1
1996 Schoepp DD, Salhoff CR, Fuson KS, Sacaan AI, Tizzano JP, Ornstein PL, May PC. Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisoquinoline- 3-carboxylic acid (LY293558) and its racemate (LY215490). Journal of Neural Transmission (Vienna, Austria : 1996). 103: 905-16. PMID 9013384 DOI: 10.1007/BF01291781  1
1996 Desai MA, Burnett JP, Mayne NG, Schoepp DD. Pharmacological characterization of desensitization in a human mGlu1 alpha-expressing non-neuronal cell line co-transfected with a glutamate transporter. British Journal of Pharmacology. 118: 1558-64. PMID 9011307  1
1996 Monn JA, Valli MJ, Johnson BG, Salhoff CR, Wright RA, Howe T, Bond A, Lodge D, Spangle LA, Paschal JW, Campbell JB, Griffey K, Tizzano JP, Schoepp DD. Synthesis of the four isomers of 4-aminopyrrolidine-2,4-dicarboxylate: identification of a potent, highly selective, and systemically-active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase. Journal of Medicinal Chemistry. 39: 2990-3000. PMID 8709133 DOI: 10.1021/jm9601765  1
1996 Ornstein PL, Arnold MB, Allen NK, Bleisch T, Borromeo PS, Lugar CW, Leander JD, Lodge D, Schoepp DD. Structure-activity studies of 6-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences, and in vivo activity. Journal of Medicinal Chemistry. 39: 2232-44. PMID 8667366 DOI: 10.1021/jm950913h  1
1996 Ornstein PL, Arnold MB, Allen NK, Bleisch T, Borromeo PS, Lugar CW, Leander JD, Lodge D, Schoepp DD. Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 1. Effects of stereochemistry, chain length, and chain substitution. Journal of Medicinal Chemistry. 39: 2219-31. PMID 8667365 DOI: 10.1021/jm950912p  1
1996 Wright RA, Schoepp DD. Differentiation of group 2 and group 3 metabotropic glutamate receptor cAMP responses in the rat hippocampus. European Journal of Pharmacology. 297: 275-82. PMID 8666060 DOI: 10.1016/0014-2999(95)00747-4  1
1996 Wermuth CG, Mann A, Schoenfelder A, Wright RA, Johnson BG, Burnett JP, Mayne NG, Schoepp DD. (2S,4S)-2-amino-4-(4,4-diphenylbut-1-yl)- pentane-1,5-dioic acid: a potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylate cyclase. Journal of Medicinal Chemistry. 39: 814-6. PMID 8632404 DOI: 10.1021/jm9508144  1
1996 Bleakman R, Schoepp DD, Ballyk B, Bufton H, Sharpe EF, Thomas K, Ornstein PL, Kamboj RK. Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid. Molecular Pharmacology. 49: 581-5. PMID 8609884  1
1996 Ornstein PL, Arnold MB, Allen NK, Schoepp DD. Synthesis and characterization of phosphonic acid-substituted amino acids as excitatory amino acid receptor antagonists Phosphorus, Sulfur and Silicon and Related Elements. 109: 309-312.  1
1996 Schoepp DD, Johnson BG, Monn JA. (1S,3R)-1-Aminocyclopentane-1,3-dicarboxylic acid-induced increases in cyclic AMP formation in the neonatal rat hippocampus are mediated by a synergistic interaction between phosphoinositide- and inhibitory cyclic AMP- coupled mGluRs Journal of Neurochemistry. 66: 1981-1985.  1
1995 Schoepp DD, Lodge D, Bleakman D, Leander JD, Tizzano JP, Wright RA, Palmer AJ, Salhoff CR, Ornstein PL. In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid. Neuropharmacology. 34: 1159-68. PMID 8532186 DOI: 10.1016/0028-3908(95)00099-R  1
1995 Schoepp DD, Johnson BG, Salhoff CR, Valli MJ, Desai MA, Burnett JP, Mayne NG, Monn JA. Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4- dicarboxylate. Neuropharmacology. 34: 843-50. PMID 8532165 DOI: 10.1016/0028-3908(95)00061-A  1
1995 Tizzano JP, Griffey KI, Schoepp DD. Induction or protection of limbic seizures in mice by mGluR subtype selective agonists. Neuropharmacology. 34: 1063-7. PMID 8532155 DOI: 10.1016/0028-3908(95)00083-I  1
1995 Ornstein PL, Arnold MB, Allen NK, Leander JD, Tizzano JP, Lodge D, Schoepp DD. (3SR,4aRS,6SR,8aRS)-6-(1H-tetrazol-5-yl)decahydroisoquinoline-3-carboxylic acid, a novel, competitive, systemically active NMDA and AMPA receptor antagonist. Journal of Medicinal Chemistry. 38: 4885-90. PMID 8523401  1
1995 Schoepp DD, Tizzano JP, Wright RA, Fix AS. Reversible and irreversible neuronal injury induced by intrahippocampal infusion of the mGluR agonist 1S,3R-ACPD in the rat. Neurodegeneration : a Journal For Neurodegenerative Disorders, Neuroprotection, and Neuroregeneration. 4: 71-80. PMID 7600186 DOI: 10.1006/neur.1995.0008  1
1995 Desai MA, Valli MJ, Monn JA, Schoepp DD. 1-BCP, a memory-enhancing agent, selectively potentiates AMPA-induced [3H]norepinephrine release in rat hippocampal slices. Neuropharmacology. 34: 141-7. PMID 7542369 DOI: 10.1016/0028-3908(94)00128-F  1
1995 Desai MA, Burnett JP, Ornstein PL, Schoepp DD. Cyclothiazide acts at a site on the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor complex that does not recognize competitive or noncompetitive AMPA receptor antagonists. The Journal of Pharmacology and Experimental Therapeutics. 272: 38-43. PMID 7529311  1
1995 Tizzano JP, Griffey KI, Schoepp DD. Receptor subtypes linked to metabotropic glutamate receptor agonist-mediated limbic seizures in mice. Annals of the New York Academy of Sciences. 765: 230-5; discussion 24. PMID 7486609 DOI: 10.1111/j.1749-6632.1995.tb16579.x  1
1995 Desai MA, Burnett JP, Mayne NG, Schoepp DD. Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on co-transfection with a glutamate transporter. Molecular Pharmacology. 48: 648-57. PMID 7476890  1
1995 Aitken PG, Breese GR, Dudek FF, Edwards F, Espanol MT, Larkman PM, Lipton P, Newman GC, Nowak TS, Panizzon KL. Preparative methods for brain slices: a discussion. Journal of Neuroscience Methods. 59: 139-49. PMID 7475244 DOI: 10.1016/0165-0270(94)00204-T  1
1995 Schoepp DD, Johnson BG, Salhoff CR, Wright RA, Goldsworthy JS, Baker SR. Second-messenger responses in brain slices to elucidate novel glutamate receptors. Journal of Neuroscience Methods. 59: 105-10. PMID 7475239 DOI: 10.1016/0165-0270(94)00200-Z  1
1995 Zeevalk GD, Schoepp D, Nicklas WJ. Excitotoxicity at both NMDA and non-NMDA glutamate receptors is antagonized by aurintricarboxylic acid: Evidence for differing mechanisms of action Journal of Neurochemistry. 64: 749-758. DOI: 10.1046/j.1471-4159.1995.64041749.x  1
1995 Richard Baker S, Goldsworthy J, Harden RC, Salhoff CR, Schoepp DD. Enzymatic resolution and pharmacological activity of the enantiomers of 3,5-dihydroxyphenylglycine, a metabotropic glutamate receptor agonist Bioorganic and Medicinal Chemistry Letters. 5: 223-228. DOI: 10.1016/0960-894X(95)00013-J  1
1995 Ornstein PL, Schoepp DD, Monn JA. Agonists and antagonists for metabotropic glutamate receptors Current Pharmaceutical Design. 1: 355-362.  1
1994 Kamboj RK, Schoepp DD, Nutt S, Shekter L, Korczak B, True RA, Rampersad V, Zimmerman DM, Wosnick MA. Molecular cloning, expression, and pharmacological characterization of humEAA1, a human kainate receptor subunit. Journal of Neurochemistry. 62: 1-9. PMID 8263508  1
1994 Schoepp DD, Lunn WH, Salhoff CR, McDonald JW. The NMDA receptor agonist DL-(tetrazol-5-yl)glycine is a highly potent excitotoxin. European Journal of Pharmacology. 270: 67-72. PMID 8157082 DOI: 10.1016/0926-6917(94)90081-7  1
1994 Watts SW, Cohen ML, Mooney PQ, Johnson BG, Schoepp DD, Baez M. Disruption of potential alpha-helix in the G loop of the guinea pig 5-hydroxytryptamine2 receptor does not prevent receptor coupling to phosphoinositide hydrolysis. Journal of Neurochemistry. 62: 934-43. PMID 8113814  1
1994 Zimmerman DM, Gidda JS, Cantrell BE, Schoepp DD, Johnson BG, Leander JD. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. Journal of Medicinal Chemistry. 37: 2262-5. PMID 8057274  1
1994 Schoepp DD, Goldsworthy J, Johnson BG, Salhoff CR, Baker SR. 3,5-dihydroxyphenylglycine is a highly selective agonist for phosphoinositide-linked metabotropic glutamate receptors in the rat hippocampus. Journal of Neurochemistry. 63: 769-72. PMID 8035201  1
1994 Watts SW, Cox DA, Johnson BG, Schoepp DD, Cohen ML. Contractile serotonin-2A receptor signal transduction in guinea pig trachea: importance of protein kinase C and extracellular and intracellular calcium but not phosphoinositide hydrolysis. The Journal of Pharmacology and Experimental Therapeutics. 271: 832-44. PMID 7965803  1
1994 Wright RA, McDonald JW, Schoepp DD. Distribution and ontogeny of 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid-sensitive and quisqualate-insensitive [3H]glutamate binding sites in the rat brain. Journal of Neurochemistry. 63: 938-45. PMID 7914226  1
1994 Bymaster FP, Wong DT, Mitch CH, Ward JS, Calligaro DO, Schoepp DD, Shannon HE, Sheardown MJ, Olesen PH, Suzdak PD, Swedberg MD, Sauerberg P. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). The Journal of Pharmacology and Experimental Therapeutics. 269: 282-9. PMID 7909558  1
1994 Schoepp DD, Sacaan AI. Metabotropic glutamate receptors and neuronal degenerative disorders. Neurobiology of Aging. 15: 261-3. PMID 7838307 DOI: 10.1016/0197-4580(94)90128-7  1
1994 Schoepp DD. Novel functions for subtypes of metabotropic glutamate receptors. Neurochemistry International. 24: 439-49. PMID 7647699 DOI: 10.1016/0197-0186(94)90092-2  1
1994 Desai MA, Burnett JP, Schoepp DD. Cyclothiazide selectively potentiates AMPA- and kainate-induced [3H]norepinephrine release from rat hippocampal slices. Journal of Neurochemistry. 63: 231-7. PMID 7515944  1
1994 Mitch CH, Bymaster FP, Calligaro DO, Quimby SJ, Schoepp DD, Wong DT, Shannon HE. Muscarinic antagonist activity of 3-(5-alkoxy-oxazol-2-yl)-1,2,5,6-tetrahydropyridines Bioorganic and Medicinal Chemistry Letters. 4: 1721-1724. DOI: 10.1016/S0960-894X(00)80368-6  1
1994 Monn JA, Schoepp DD. Chapter 6. Recent Progress in Excitatory Amino Acid Research Annual Reports in Medicinal Chemistry. 29: 53-64. DOI: 10.1016/S0065-7743(08)60719-8  1
1994 Ornstein PL, Monn JA, Schoepp DD. Antagonists of the NMDA receptor complex Drug News and Perspectives. 7: 5-12.  1
1993 McDonald JW, Fix AS, Tizzano JP, Schoepp DD. Seizures and brain injury in neonatal rats induced by 1S,3R-ACPD, a metabotropic glutamate receptor agonist. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 13: 4445-55. PMID 8410197  1
1993 Ornstein PL, Arnold MB, Augenstein NK, Lodge D, Leander JD, Schoepp DD. (3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 - carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist. Journal of Medicinal Chemistry. 36: 2046-8. PMID 8393116  1
1993 Zeevalk GD, Schoepp D, Nicklas WJ. Aurintricarboxylic acid prevents NMDA-mediated excitotoxicity: Evidence for its action as an NMDA receptor antagonist Journal of Neurochemistry. 61: 386-389. PMID 8390567  1
1993 Schoepp DD. The biochemical pharmacology of metabotropic glutamate receptors. Biochemical Society Transactions. 21: 97-102. PMID 8383618  1
1993 Fix AS, Schoepp DD, Olney JW, Vestre WA, Griffey KI, Johnson JA, Tizzano JP. Neonatal exposure to D,L-2-amino-3-phosphonopropionate (D,L-AP3) produces lesions in the eye and optic nerve of adult rats. Brain Research. Developmental Brain Research. 75: 223-33. PMID 8261613 DOI: 10.1016/0165-3806(93)90027-8  1
1993 McDonald JW, Schoepp DD. Aminooxyacetic acid produces excitotoxic brain injury in neonatal rats. Brain Research. 624: 239-44. PMID 8252396 DOI: 10.1016/0006-8993(93)90083-Y  1
1993 Tizzano JP, Griffey KI, Johnson JA, Fix AS, Helton DR, Schoepp DD. Intracerebral 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) produces limbic seizures that are not blocked by ionotropic glutamate receptor antagonists. Neuroscience Letters. 162: 12-6. PMID 8121613 DOI: 10.1016/0304-3940(93)90548-Y  1
1993 Schoepp DD, Johnson BG. Pharmacology of metabotropic glutamate receptor inhibition of cyclic AMP formation in the adult rat hippocampus. Neurochemistry International. 22: 277-83. PMID 8095174 DOI: 10.1016/0197-0186(93)90056-B  1
1993 Schoepp DD, Conn PJ. Metabotropic glutamate receptors in brain function and pathology. Trends in Pharmacological Sciences. 14: 13-20. PMID 7680175 DOI: 10.1016/0165-6147(93)90107-U  1
1993 Schoepp DD, Johnson BG. Metabotropic glutamate receptor modulation of cAMP accumulation in the neonatal rat hippocampus. Neuropharmacology. 32: 1359-65. PMID 7512234 DOI: 10.1016/0028-3908(93)90031-W  1
1993 Ornstein PL, Arnold MB, Augenstein NK, Deeter JB, Leander JD, Lodge D, Calligaro DO, Schoepp DD. Unusual stereochemical preferences of decahydroisoquinoline-3-cargoxylic acid competitive NMDA antagonists Bioorganic and Medicinal Chemistry Letters. 3: 2067-2072. DOI: 10.1016/S0960-894X(01)81017-9  1
1993 Ornstein PL, Arnold MB, Evrard D, Leander JD, Lodge D, Schoepp DD. Tetrazole amino acids as competitive NMDA antagonists Bioorganic and Medicinal Chemistry Letters. 3: 43-48. DOI: 10.1016/S0960-894X(00)80089-X  1
1992 Schoepp DD, True RA. 1S,3R-ACPD-sensitive (metabotropic) [3H]glutamate receptor binding in membranes. Neuroscience Letters. 145: 100-4. PMID 1461560 DOI: 10.1016/0304-3940(92)90213-Q  1
1992 Sacaan AI, Schoepp DD. Activation of hippocampal metabotropic excitatory amino acid receptors leads to seizures and neuronal damage. Neuroscience Letters. 139: 77-82. PMID 1407685 DOI: 10.1016/0304-3940(92)90862-2  1
1992 Ornstein PL, Schoepp DD, Arnold MB, Augenstein NK, Lodge D, Millar JD, Chambers J, Campbell J, Paschal JW, Zimmerman DM. 6-substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists. Journal of Medicinal Chemistry. 35: 3547-60. PMID 1404235  1
1992 Ornstein PL, Schoepp DD, Arnold MB, Jones ND, Deeter JB, Lodge D, Leander JD. NMDA antagonist activity of (+/-)-(2SR,4RS)-4-(1H-tetrazol-5-ylmethyl)piperidine-2-carboxylic acid resides with the (-)-2R,4S-isomer. Journal of Medicinal Chemistry. 35: 3111-5. PMID 1387167  1
1992 McDonald JW, Schoepp DD. The metabotropic excitatory amino acid receptor agonist 1S,3R-ACPD selectively potentiates N-methyl-D-aspartate-induced brain injury. European Journal of Pharmacology. 215: 353-4. PMID 1383003 DOI: 10.1016/0014-2999(92)90058-C  1
1992 McQuaid LA, Smith EC, South KK, Mitch CH, Schoepp DD, True RA, Calligaro DO, O'Malley PJ, Lodge D, Ornstein PL. Synthesis and excitatory amino acid pharmacology of a series of heterocyclic-fused quinoxalinones and quinazolinones. Journal of Medicinal Chemistry. 35: 3319-24. PMID 1382133  1
1992 Lunn WH, Schoepp DD, Calligaro DO, Vasileff RT, Heinz LJ, Salhoff CR, O'Malley PJ. DL-tetrazol-5-ylglycine, a highly potent NMDA agonist: its synthesis and NMDA receptor efficacy. Journal of Medicinal Chemistry. 35: 4608-12. PMID 1361579 DOI: 10.1021/jm00102a015  1
1992 Kamboj RK, Schoepp DD, Nutt S, Shekter L, Korczak B, True RA, Zimmerman DM, Wosnick MA. Molecular structure and pharmacological characterization of humEAA2, a novel human kainate receptor subunit. Molecular Pharmacology. 42: 10-5. PMID 1321949  1
1992 Sacaan AI, Bymaster FP, Schoepp DD. Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine. Journal of Neurochemistry. 59: 245-51. PMID 1319468 DOI: 10.1111/j.1471-4159.1992.tb08897.x  1
1992 Schoepp DD, Johnson BG, Monn JA. Inhibition of cyclic AMP formation by a selective metabotropic glutamate receptor agonist. Journal of Neurochemistry. 58: 1184-6. PMID 1310724  1
1992 Gehlert DR, Schoepp DD. Striatal quinolinic acid lesions increase [3H]WIN 35,428 binding to the dopamine transporter. Neurochemistry International. 21: 581-4. PMID 1303740 DOI: 10.1016/0197-0186(92)90091-5  1
1992 Zimmerman DM, Schoepp DD, Leander JD, Ornstein PL. The discovery and characterization of the competitive NMDA antagonists LY274614, LY233536 and LY233053 Molecular Neuropharmacology. 2: 77-81.  1
1992 Schoepp DD, Johnson BG, Sacaan AI, True RA, Monn JA. In vitro and in vivo pharmacology of 1S,3R-and 1R,3S-ACPD: Evidence for a role of metabotropic glutamate receptors in striatal motor function Molecular Neuropharmacology. 2: 33-37.  1
1991 Schoepp DD, Johnson BG. In vivo 2-amino-3-phosphonopropionic acid administration to neonatal rats selectively inhibits metabotropic excitatory amino acid receptors ex vivo in brain slices. Neurochemistry International. 18: 411-7. PMID 20504719 DOI: 10.1016/0197-0186(91)90174-C  1
1991 Schoepp DD, Johnson BG, Salhoff CR, McDonald JW, Johnston MV. In vitro and in vivo pharmacology of trans- and cis-(+-)-1-amino-1,3-cyclopentanedicarboxylic acid: dissociation of metabotropic and ionotropic excitatory amino acid receptor effects. Journal of Neurochemistry. 56: 1789-96. PMID 1849553  1
1991 Schoepp DD, Ornstein PL, Salhoff CR, Leander JD. Neuroprotectant effects of LY274614, a structurally novel systemically active competitive NMDA receptor antagonist. Journal of Neural Transmission. General Section. 85: 131-43. PMID 1834088 DOI: 10.1007/BF01244705  1
1991 Ornstein PL, Schoepp DD, Arnold MB, Leander JD, Lodge D, Paschal JW, Elzey T. 4-(Tetrazolylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action. Journal of Medicinal Chemistry. 34: 90-7. PMID 1825117  1
1991 Schoepp DD, Smith CL, Lodge D, Millar JD, Leander JD, Sacaan AI, Lunn WH. D,L-(tetrazol-5-yl) glycine: a novel and highly potent NMDA receptor agonist. European Journal of Pharmacology. 203: 237-43. PMID 1686860 DOI: 10.1016/0014-2999(91)90719-7  1
1991 Schoepp DD, Johnson BG, True RA, Monn JA. Comparison of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD)- and 1R,3S-ACPD-stimulated brain phosphoinositide hydrolysis. European Journal of Pharmacology. 207: 351-3. PMID 1664338 DOI: 10.1016/0922-4106(91)90010-F  1
1991 Sacaan AI, Monn JA, Schoepp DD. Intrastriatal injection of a selective metabotropic excitatory amino acid receptor agonist induces contralateral turning in the rat. The Journal of Pharmacology and Experimental Therapeutics. 259: 1366-70. PMID 1662277  1
1990 Schoepp DD, Gamble AY, Salhoff CR, Johnson BG, Ornstein PL. Excitatory amino acid-induced convulsions in neonatal rats mediated by distinct receptor subtypes. European Journal of Pharmacology. 182: 421-7. PMID 2171944 DOI: 10.1016/0014-2999(90)90039-9  1
1990 Schoepp DD, Johnson BG, Smith EC, McQuaid LA. Stereoselectivity and mode of inhibition of phosphoinositide-coupled excitatory amino acid receptors by 2-amino-3-phosphonopropionic acid. Molecular Pharmacology. 38: 222-8. PMID 2166902  1
1990 Schmidhammer H, Leander JD, Mayer-Valkanover K, Nussbaumer C, Schmidt C, Schoepp DD, Schratz A, Walla-Kugler M. 5-Methylated naloxone, naltrexone, oxymorphone, and their 14-O-methyl ethers. Progress in Clinical and Biological Research. 328: 41-4. PMID 2154800  1
1990 Ornstein PL, Schoepp DD, Leander JD, Wong T, Zimmerman DM, Lodge D. LY233053: a structurally novel, potent and selective competitive N-methyl-D-aspartate receptor antagonist. Progress in Clinical and Biological Research. 361: 429-33. PMID 2149764  1
1990 Schoepp DD, Ornstein PL, Leander JD, Lodge D, Salhoff CR, Zeman S, Zimmerman DM. Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action. The Journal of Pharmacology and Experimental Therapeutics. 255: 1301-8. PMID 2148188  1
1990 Schoepp D, Bockaert J, Sladeczek F. Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors Trends in Pharmacological Sciences. 11: 508-515. PMID 1964257 DOI: 10.1016/0165-6147(90)90052-A  1
1990 Schoepp DD, Hillman CC. Developmental and pharmacological characterization of quisqualate, ibotenate, and trans-1-amino-1, 3-cyclopentanedicarboxylic acid stimulations of phosphoinositide hydrolysis in rat cortical brain slices Biogenic Amines. 7: 331-340.  1
1989 Schoepp DD. Protein kinase C-mediated inhibition of excitatory amino acid-stimulated phosphoinositide hydrolysis in the neonatal rat hippocampus. Neurochemistry International. 15: 131-6. PMID 20504474 DOI: 10.1016/0197-0186(89)90091-0  1
1989 Schoepp DD, Johnson BG. Inhibition of excitatory amino acid-stimulated phosphoinositide hydrolysis in the neonatal rat hippocampus by 2-amino-3-phosphonopropionate. Journal of Neurochemistry. 53: 1865-70. PMID 2572680  1
1989 Schoepp DD, Salhoff CR, Hillman CC, Ornstein PL. CGS-19755 and MK-801 selectively prevent rat striatal cholinergic and gabaergic neuronal degeneration induced by N-methyl-D-aspartate and ibotenate in vivo. Journal of Neural Transmission. General Section. 78: 183-93. PMID 2553073 DOI: 10.1007/BF01249228  1
1989 Secrest RJ, Schoepp DD, Cohen ML. Comparison of contractions to serotonin, carbamylcholine and prostaglandin F2 alpha in rat stomach fundus. The Journal of Pharmacology and Experimental Therapeutics. 250: 971-8. PMID 2550624  1
1989 Schoepp DD, Johnson BG. Comparison of excitatory amino acid-stimulated phosphoinositide hydrolysis and N-[3H]acetylaspartylglutamate binding in rat brain: selective inhibition of phosphoinositide hydrolysis by 2-amino-3-phosphonopropionate. Journal of Neurochemistry. 53: 273-8. PMID 2542463  1
1989 Schmidhammer H, Leander JD, Mayer-Valkanover K, Nussbaumer C, Schmidt C, Schoepp DD, Schratz A, Walla-Kugler M. 5-methyl analogs of naloxone, naltrexone and oxymorphone | 5-METHYLANALOGA DES NALOXONS, NALTREXONS UND OXYMORPHONS Scientia Pharmaceutica. 57: 209.  1
1988 Schoepp DD, Johnson BG. Selective inhibition of excitatory amino acid-stimulated phosphoinositide hydrolysis in the rat hippocampus by activation of protein kinase C. Biochemical Pharmacology. 37: 4299-305. PMID 2904266 DOI: 10.1016/0006-2952(88)90610-7  1
1988 Schoepp DD, Johnson BG. Excitatory amino acid agonist-antagonist interactions at 2-amino-4-phosphonobutyric acid-sensitive quisqualate receptors coupled to phosphoinositide hydrolysis in slices of rat hippocampus. Journal of Neurochemistry. 50: 1605-13. PMID 2834517  1
1988 Gruetter CA, Ryan ET, Lemke SM, Bailly DA, Fox MK, Schoepp DD. Endothelium-dependent modulation of angiotensin II-induced contraction in blood vessels. European Journal of Pharmacology. 146: 85-95. PMID 2832199 DOI: 10.1016/0014-2999(88)90489-X  1
1988 Schmidhammer H, Deeter JB, Jones ND, Leander JD, Schoepp DD, Swartzendruber JK. Synthesis, structure elucidation, and pharmacological evaluation of 5-methyl-oxymorphone (= 4,5α-epoxy-3,14-dihydroxy-5,17-dimethylmorphinan-6-one) Helvetica Chimica Acta. 71: 1801-1804.  1
1987 Schoepp DD, Bailly DA. Estrogen modulation of angiotensin-stimulated phosphoinositide hydrolysis in slices of rat anterior pituitary. Neurochemistry International. 11: 149-54. PMID 20501155 DOI: 10.1016/0197-0186(87)90003-9  1
1987 Gruetter CA, Ryan ET, Schoepp DD. Endothelium enhances tachyphylaxis to angiotensins II and III in rat aorta. European Journal of Pharmacology. 143: 139-42. PMID 3691648 DOI: 10.1016/0014-2999(87)90745-X  1
1987 Melethil S, Schoepp D. Pharmacokinetics of Gold Sodium Thiomalate in Rabbits Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists. 4: 332-336. PMID 3150043 DOI: 10.1023/A:1016453421958  1
1985 Schoepp DD, Azzaro AJ. Further studies on the nature of postsynaptic dopamine uptake and metabolism in rat striatum: sodium dependency and investigation of a possible role for carrier-mediated uptake into serotonin neurons. Journal of Neurochemistry. 44: 1747-52. PMID 3989560  1
1985 Azzaro AJ, King J, Kotzuk J, Schoepp DD, Frost J, Schochet S. Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism. Journal of Neurochemistry. 45: 949-56. PMID 3928811 DOI: 10.1111/j.1471-4159.1985.tb04086.x  1
1985 Schoepp DD, Rutledge CO. Comparison of postnatal changes in alpha 1-adrenoceptor binding and adrenergic stimulation of phosphoinositide hydrolysis in rat cerebral cortex. Biochemical Pharmacology. 34: 2705-11. PMID 2990495 DOI: 10.1016/0006-2952(85)90571-4  1
1984 Schoepp DD, Rutledge CO. Relationship between developmental changes in angiotensin II-induced contractions and stimulation of phosphatidylinositol labeling of rat aorta. The Journal of Pharmacology and Experimental Therapeutics. 229: 880-6. PMID 6374101  1
1984 Schoepp DD, Knepper SM, Rutledge CO. Norepinephrine stimulation of phosphoinositide hydrolysis in rat cerebral cortex is associated with the alpha1-adrenoceptor. Journal of Neurochemistry. 43: 1758-61. PMID 6092548  1
1983 Schoepp DD, Azzaro AJ. Effects of intrastriatal kainic acid injection on [3H]dopamine metabolism in rat striatal slices: evidence for postsynaptic glial cell metabolism by both the type A and B forms of monoamine oxidase. Journal of Neurochemistry. 40: 1340-8. PMID 6131940  1
1982 Schoepp DD, Azzaro AJ. Role of type A and type B monoamine oxidase in the metabolism of released [3H]dopamine from rat striatal slices. Biochemical Pharmacology. 31: 2961-8. PMID 6814449 DOI: 10.1016/0006-2952(82)90270-2  1
1981 Schoepp DD, Azzaro AJ. Alteration of dopamine synthesis in rat striatum subsequent to selective type A monoamine oxidase inhibition. Journal of Neurochemistry. 37: 527-30. PMID 6790675  1
1981 Schoepp DD, Azzaro AJ. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum. Journal of Neurochemistry. 36: 2025-31. PMID 6787175  1
Show low-probability matches.